SVB Leerink analyst Joseph Schwartz notes that FDA's Allergenic Products Advisory Committee released briefing documents pertaining to its upcoming AdCom panel discussion for Aimmune's (AIMT) Palforzia on Friday. Because efficacy has been robust for Palforzia, the analyst thinks investors will be acutely focused on safety, and believes the details surrounding Palforzia safety bode well for DBV Technologies' (DBVT) Viaskin Peanut as it could provide a convenient and safer alternative for peanut allergic patients. Despite slower onset of efficacy, Viaskin Peanut's favorable safety profile could promote longer-term use which previously has been shown to continue to improve on efficacy, he contends. Schwartz has an Outperform rating on DBV Technologies' shares.